Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
worldwide. In the past decade, there have been improvements in non-drug therapies and …

Platelet-derived growth factors (PDGFs) and PDGF receptors (PDGFRs) are expressed in a
variety of tumors. Activation of the PDGF/PDGFR signaling pathway is associated with …

Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of
idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of …

Purpose: Because of the increased number of sequential treatments used for advanced
hepatocellular carcinoma (HCC), there is a need for surrogate endpoints of overall survival …

Importance The recent development of targeted therapy and immunotherapy has made
neoadjuvant therapy an attractive option for patients with hepatocellular carcinoma (HCC) …

Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial
growth factor-, and platelet-derived growth factor receptors. These three receptors promote …

BACKGROUND The majority of clinical trials of first-line systemic treatments for
hepatocellular carcinoma (HCC) used placebo or sorafenib as comparators, and there are …

Objective The aim of this study was to compare and rank different targeted therapies or
immunotherapies for advanced hepatocellular carcinoma based on efficacy. Methods A …

Systemic therapy for hepatocellular carcinoma (HCC) used to be limited to patients with
advanced diseases and multi-kinase inhibitors targeting tumor angiogenesis the major …

Background: Emerging data suggest that outcomes for advanced hepatocellular carcinoma
(HCC) treated with sorafenib may have improved over time. We aimed to provide robust …